Cryoglobulins are antibodies in your blood that clump together when your body temperature drops below 98.6°F (37°C) and dissolve again when you warm back up. This unusual behavior can block small blood vessels, trigger inflammation, and damage organs. The condition of having these proteins in your blood is called cryoglobulinemia, and it ranges from a silent lab finding to a serious systemic disease.
How Cryoglobulins Work
Under normal circumstances, antibodies (also called immunoglobulins) flow freely through the bloodstream and help fight infections. Cryoglobulins are structurally similar to normal antibodies, but something about their makeup causes them to stick together and form solid clumps when temperatures dip even slightly below core body temperature. This precipitation is reversible: warm the blood back to 37°C and the clumps dissolve.
The areas of the body most affected are the ones that naturally run cooler: the skin, joints, and peripheral nerves in the hands and feet. In the kidneys, the issue is less about temperature and more about concentration. Blood gets filtered through tiny vessels there, and cryoglobulins can build up and deposit in those structures. The resulting damage comes in two forms depending on the type: direct blockage of small blood vessels, or immune-complex deposits that trigger inflammation in vessel walls.
The Three Types
Cryoglobulins are classified into three types based on a system proposed by Brouet and colleagues in 1974. The type matters because each one behaves differently and points to different underlying causes.
- Type I consists of a single type of monoclonal (identical) antibody, most often IgM. It tends to cause problems by physically clogging blood vessels, leading to skin discoloration, reduced blood flow to the extremities, and sometimes skin death. Type I is almost always linked to blood cancers involving antibody-producing cells, such as certain lymphomas or myeloma.
- Type II contains a mix of monoclonal and polyclonal antibodies. The monoclonal component acts as an autoantibody, meaning it attacks the body’s own normal antibodies. This creates immune complexes that deposit in vessel walls and cause inflammation. Type II is strongly associated with chronic hepatitis C infection.
- Type III is made entirely of polyclonal (varied) antibodies. It behaves similarly to Type II and is also linked to hepatitis C, autoimmune diseases, and chronic infections. The distinction between Type II and Type III is largely technical, hinging on whether the autoantibody component is monoclonal or polyclonal.
Types II and III are collectively called “mixed cryoglobulinemia” because they contain multiple antibody classes. They account for the vast majority of cases.
What Causes Cryoglobulin Production
Hepatitis C is the dominant driver. At least 90% of mixed cryoglobulinemia cases are tied to chronic hepatitis C infection, and low levels of circulating cryoglobulins can be detected in over 50% of people with the virus. Only about 5% of hepatitis C patients develop overt symptoms from their cryoglobulins, though. The rest carry these proteins silently.
Beyond hepatitis C, cryoglobulins can appear in people with autoimmune diseases like lupus or rheumatoid arthritis, B-cell lymphomas, and other chronic infections. A small fraction of cases, historically called “essential” cryoglobulinemia because no cause could be identified, is now recognized to make up fewer than 5% of patients in areas where hepatitis C testing is thorough. The overall prevalence of truly unexplained mixed cryoglobulinemia is estimated at roughly 1 in 100,000, though adequate epidemiological studies are still lacking.
Symptoms and How It Feels
The classic presentation is known as Meltzer’s triad: purpura (a rash of small reddish-purple spots), joint pain, and weakness. This triad shows up early in about 80% of patients with mixed cryoglobulinemia. Purpura is the single most common symptom, appearing in roughly 75% of cases, typically starting on the lower legs and sometimes extending up toward the torso and arms. These spots are “palpable,” meaning you can feel them as slightly raised bumps on the skin.
Other common features include peripheral neuropathy (57% of patients), which usually presents as numbness, tingling, or burning in the hands and feet. Joint pain without visible joint swelling affects about 44% of patients. Skin ulcers develop in about 16%.
Type I cryoglobulinemia looks different from the mixed types. Because it causes direct vessel blockage rather than immune-mediated inflammation, it tends to produce more dramatic skin findings: a lace-like purplish discoloration of the skin, areas of tissue death, and cold-triggered color changes in the fingers or toes. Skin symptoms occur in 70% to 85% of Type I cases.
Kidney and Other Organ Damage
Kidney involvement occurs in about 30% of mixed cryoglobulinemia patients and carries a poor prognosis. The immune complexes deposit in the kidney’s filtering units, causing inflammation that can show up as protein or blood in the urine, or a gradual decline in kidney function. In severe cases, it can progress to a form of kidney inflammation that significantly impairs the organ’s ability to filter waste.
The most serious long-term risk is the development of non-Hodgkin lymphoma. People with cryoglobulins face a 35-fold higher risk of this blood cancer compared to the general population. One study following mixed cryoglobulinemia patients for 10 years found that 10% developed non-Hodgkin lymphoma during follow-up. This risk is highest in patients with Type II cryoglobulins.
How Cryoglobulins Are Tested
Testing for cryoglobulins is straightforward in concept but surprisingly easy to get wrong. A blood sample is drawn and watched to see whether proteins precipitate out when cooled. The percentage of the sample that forms a solid clump is called the cryocrit. A cryocrit of 1% or more is considered abnormal, but even tiny amounts of cryoglobulins can cause problems depending on the type and clinical context. There are no widely standardized reference ranges for cryocrit values.
The critical catch is sample handling. Blood must be kept at body temperature (37°C) from the moment it’s drawn until the serum is separated in the lab. If the sample cools during transport or storage, the cryoglobulins precipitate prematurely and get discarded with the clot, producing a false negative result. This is the single most common source of error in cryoglobulin testing. If your doctor suspects cryoglobulinemia, it’s worth confirming that the lab follows warm-handling protocols.
Treatment Approaches
Treatment targets the underlying disease first. For hepatitis C-associated cryoglobulinemia, antiviral therapy to clear the virus is the foundation. For cryoglobulinemia driven by a blood cancer, treatment of that cancer takes priority. For autoimmune-related cases, immunosuppressive therapy addresses the root cause.
When symptoms are moderate to severe, additional treatments work to calm the immune system and remove the harmful proteins. Plasma exchange physically filters cryoglobulins out of the blood and is used for serious complications like significant kidney disease, skin ulcers, pulmonary bleeding, or intestinal inflammation. It provides rapid relief while slower-acting treatments take effect, and it can also be used as ongoing maintenance to prevent flares.
Rituximab, a medication that depletes the B cells responsible for producing the problematic antibodies, has become one of the main immunosuppressive options. High-dose corticosteroids can also be used to quickly shut down the inflammatory process in severe cases. In some situations, plasma exchange is performed before starting rituximab because the drug can initially cause a temporary spike in the harmful antibodies, potentially worsening symptoms before improving them.
Treatment is reserved for people with active symptoms. Many individuals with detectable cryoglobulins but no symptoms simply need monitoring, with attention focused on managing whatever underlying condition is producing the proteins.